'Secondary' acute lymphoblastic/lymphocytic leukemia - done playing second fiddle? 2023

Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
Icahn School of Medicine Mount Sinai West and Morningside, 1000 Tenth Avenue, New York, NY 10019, United States of America. Electronic address: yosefjosephrene.amelriazat-kesh@mountsinai.org.

Acute lymphoblastic/lymphocytic leukemia (ALL) occurring post-cancer diagnosis (secondary ALL - sALL) is increasingly recognized as a discrete entity, constituting up to as much as 5-10% of all new ALL diagnoses, and carrying its own biologic, prognostic and therapeutic significance. In this review, we will outline the history and current state of research into sALL. We will explore the evidence for differences underlining its existence as a distinct subgroup, as well as examining what might be driving such differences etiologically, including prior chemotherapy. We will examine these distinctions on population-, chromosomal-, and molecular-levels, and we will consider whether they translate to differences in clinical outcome, and whether they do - or should - warrant differences in treatment selection.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016609 Neoplasms, Second Primary Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause. Neoplasms, Metachronous,Neoplasms, Metachronous Second Primary,Neoplasms, Therapy-Related,Neoplasms, Treatment-Related,Second Malignancy,Second Neoplasm,Second Primary Neoplasms,Therapy-Associated Neoplasms,Therapy-Related Cancer,Treatment-Associated Neoplasms,Treatment-Related Cancer,Cancer, Second Primary,Metachronous Neoplasms,Metachronous Second Primary Neoplasms,Neoplasms, Therapy-Associated,Neoplasms, Treatment-Associated,Second Cancer,Second Primary Neoplasms, Metachronous,Therapy-Associated Cancer,Therapy-Related Neoplasms,Treatment-Associated Cancer,Treatment-Related Neoplasms,Cancer, Second,Cancer, Therapy-Associated,Cancer, Therapy-Related,Cancer, Treatment-Associated,Cancer, Treatment-Related,Cancers, Second,Cancers, Second Primary,Cancers, Therapy-Associated,Cancers, Therapy-Related,Cancers, Treatment-Associated,Cancers, Treatment-Related,Malignancies, Second,Malignancy, Second,Metachronous Neoplasm,Neoplasm, Metachronous,Neoplasm, Second,Neoplasm, Second Primary,Neoplasm, Therapy-Associated,Neoplasm, Therapy-Related,Neoplasm, Treatment-Associated,Neoplasm, Treatment-Related,Neoplasms, Second,Neoplasms, Therapy Associated,Neoplasms, Therapy Related,Neoplasms, Treatment Associated,Neoplasms, Treatment Related,Second Cancers,Second Malignancies,Second Neoplasms,Second Primary Cancer,Second Primary Cancers,Second Primary Neoplasm,Therapy Associated Cancer,Therapy Associated Neoplasms,Therapy Related Cancer,Therapy Related Neoplasms,Therapy-Associated Cancers,Therapy-Associated Neoplasm,Therapy-Related Cancers,Therapy-Related Neoplasm,Treatment Associated Cancer,Treatment Associated Neoplasms,Treatment Related Cancer,Treatment Related Neoplasms,Treatment-Associated Cancers,Treatment-Associated Neoplasm,Treatment-Related Cancers,Treatment-Related Neoplasm

Related Publications

Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
April 2024, Anesthesiology,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
January 2000, Ryoikibetsu shokogun shirizu,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
January 2010, Journal of midwifery & women's health,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
June 2000, Trends in microbiology,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
August 1991, Cancer genetics and cytogenetics,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
September 1998, The New England journal of medicine,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
September 2000, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
February 1982, American journal of diseases of children (1960),
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
February 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Yosef Joseph Rene Amel Riazat-Kesh, and John Mascarenhas, and Michal Bar-Natan
December 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!